Wegovy Flextouch (0.25mg)
SKU: wegovy-25
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
This medicinal product is subject to additional monitoring. Healthcare professionals are asked to report any suspected adverse reactions using the Yellow Card Scheme: www.mhra.gov.uk/yellowcard
Wegovy (0.25mg) comes with 4 Novofine needles as supplied by the manufacturer
EMC: https://www.medicines.org.uk/emc/product/13799/smpc#about-medicine
Patient Information Leaflet: https://www.medicines.org.uk/emc/files/pil.13799.pdf
Practitioners please note:
Additional safe guidelines:- when prescribing Wegovy adults should have a BMI over 30, or those with a BMI of 27+ with at least one weight-related condition.BMI must be stated on the prescription and only x2 pens per patient per prescription.
Login for price
Description
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
This medicinal product is subject to additional monitoring. Healthcare professionals are asked to report any suspected adverse reactions using the Yellow Card Scheme: www.mhra.gov.uk/yellowcard
Wegovy (0.25mg) comes with 4 Novofine needles as supplied by the manufacturer
EMC: https://www.medicines.org.uk/emc/product/13799/smpc#about-medicine
Patient Information Leaflet: https://www.medicines.org.uk/emc/files/pil.13799.pdf
Description
Wegovy (Semaglutide) 0.25mg FlexTouch solution for injection in pre-filled pen
Wegovy is a prescription only medicine indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of
- ≥ 30 kg/m2 (obesity), or
- ≥ 27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).
Mechanism of action:
Semaglutide is a GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1.
GLP-1 is a physiological regulator of appetite and calorie intake, and the GLP-1 receptor is present in several areas of the brain involved in appetite regulation.
Semaglutide has direct effects on areas in the brain involved in homeostatic regulation of food intake in the hypothalamus and the brainstem, and direct and indirect effects on areas involved in hedonic regulation of food intake, including the septum, thalamus and amygdala.
Contraindications:
Hypersensitivity to the active substance or to any of the excipients.
Store in a refrigerator at 2–8°
Practitioners please note:
Additional safe guidelines:-
When prescribing Wegovy adults should have a BMI over 30, or those with a BMI of 27+ with at least one weight-related condition.BMI must be stated on the prescription and only x2 pens per patient per prescription.
Please note safe disposal of needles is required where necessary, we stock 1 litre sharps bins, please add at check out.
Additional information
Purchase Option |
---|